State Street Amends REGENXBIO Stake, Maintains Passive Position
Ticker: RGNX · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1590877
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street still holds REGENXBIO shares, showing continued institutional interest.**
AI Summary
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 25, 2024, indicating its ownership of REGENXBIO Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, showing their continued significant, though passive, stake in the gene therapy company. For investors, this means a large institutional holder maintains confidence in REGENXBIO, which can signal stability but also means a potential large seller if State Street were to significantly reduce its position.
Why It Matters
This filing confirms State Street Corporation's ongoing institutional investment in REGENXBIO, signaling continued confidence from a major financial player, which can be a positive indicator for other investors.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor, indicating no immediate significant change in their investment strategy or the company's outlook.
Analyst Insight
Investors should note that a major institution like State Street continues to hold REGENXBIO shares, suggesting a baseline level of confidence, but this filing doesn't indicate any new aggressive moves or significant changes in the company's prospects.
Key Players & Entities
- State Street Corporation (company) — the reporting person and institutional investor
- REGENXBIO Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 25, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- State Street Corporation will maintain a passive investment strategy in REGENXBIO Inc. for the foreseeable future. (State Street Corporation) — high confidence, target: 2025-01-25
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, indicating a change or update to a previous filing by a passive institutional investor.
Who is the reporting person in this filing?
The reporting person is STATE STREET CORPORATION, a financial institution with a business address at 1 CONGRESS STREET, SUITE 1, BOSTON, MA 02114.
What is the subject company whose securities are being reported?
The subject company is REGENXBIO Inc., a company in the biological products industry, located at 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD 20850.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the common stock of REGENXBIO Inc. is 75901B107.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding REGENXBIO Inc. (RGNX).